MUMBAI — Sun Pharmaceutical Industries reported a 26 percent year-on-year increase in consolidated profit after tax to Rs 2,714 crore for the January-March quarter, though the performance reflected sequential weakness compared to the preceding quarter.
The pharmaceutical major's quarterly profit declined 19 percent from Rs 3,369 crore recorded in Q3FY26, while revenue contracted 6 percent sequentially from Rs 15,520 crore in the October-December period, indicating temporary headwinds in the final quarter of the fiscal year.
The company's board approved a dividend of Rs 5 per equity share, rewarding shareholders despite the sequential moderation in performance.
The divergent trends—strong annual growth coupled with quarterly decline—suggest the pharmaceutical sector continues to navigate uneven demand patterns and margin pressures. Year-on-year comparisons indicate robust underlying business momentum, while the sequential drop points to potential seasonality or one-time factors affecting the quarter.
For investors, the annual growth trajectory remains encouraging for India's largest pharmaceutical company by market capitalization. The dividend announcement reinforces management confidence in sustained cash generation despite short-term fluctuations in operational performance.